The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at ...
Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...
The Food and Drug Administration approved Novavax’s new COVID-19 vaccine Friday, a week after giving Pfizer and Moderna the OK on their shots, though all drugmakers say their shots will be available ...
WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty ...
Novavax's vaccine didn't enter the market until after the inoculations developed by Moderna and Pfizer had already taken dominant market shares. This meant it missed out on the biggest revenue ...
Why does Sanofi want the Novavax COVID vaccine? The Novavax COVID-19 vaccine, which is called Nuvaxovid outside of the U.S., isn't like the mRNA vaccines from Moderna and Pfizer. Instead of goading ...
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...
Feb 22 (Reuters) - Novavax (NVAX.O), opens new tab has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over ...
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed ...
Shares of Novavax fell after the vaccine maker reported fourth-quarter revenue and earnings that missed Wall Street's estimates. The company also said it expects full-year 2024 sales to come in flat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results